Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Kowa Research Institute, Inc.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Subsidiary
Established
1981-01-01
Employees
1
Market Cap
-
Website
http://www.kowaus.com
Clinical Trials
Related News
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: SK-0403
Drug: Placebo
Drug: Sitagliptin
Subscribe
First Posted Date
2010-07-23
Last Posted Date
2011-08-17
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
620
Registration Number
NCT01169090
Subscribe
A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403
Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: SK-0403
Subscribe
First Posted Date
2010-05-26
Last Posted Date
2011-02-10
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
30
Registration Number
NCT01131091
Subscribe
Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
Phase 4
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Pitavastatin (NK-104)
Drug: Lopinavir/ritonavir
Subscribe
First Posted Date
2010-01-27
Last Posted Date
2021-06-22
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
24
Registration Number
NCT01057433
Subscribe
Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers
Phase 4
Completed
Conditions
Severe Renal Impairment
Interventions
Drug: Pitavastatin 4mg
Subscribe
First Posted Date
2010-01-06
Last Posted Date
2012-08-13
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
16
Registration Number
NCT01043094
Subscribe
A Trial of the Safety and Efficacy of K-604 for the Treatment of Atherosclerosis
Phase 2
Completed
Conditions
Atherosclerosis
Interventions
Drug: K-604
Other: Placebo
Subscribe
First Posted Date
2009-02-26
Last Posted Date
2011-08-17
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
210
Registration Number
NCT00851500
Subscribe
Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication
Phase 2
Completed
Conditions
Intermittent Claudication
Interventions
Drug: K-134
Drug: Cilostazol 100 mg BID
Drug: Placebo
Subscribe
First Posted Date
2008-10-31
Last Posted Date
2012-03-22
Lead Sponsor
Kowa Research Institute, Inc.
Target Recruit Count
387
Registration Number
NCT00783081
Subscribe
Prev
1
2
3
4
5
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy